These medications for BPH have known risks and may have new side effects.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
The research created new azasteroids and pseudoazulenyl nitrones, which could be useful in medicine.
14 citations
,
August 2020 in “Dermatologic Therapy” Low-dose oral minoxidil is a safe treatment for hair loss, with the main side effect being excessive hair growth. Other side effects like foot swelling, low blood pressure when standing, and heart rate changes are rare.
January 2023 in “Revista Eletrônica Acervo Saúde” Oral Minoxidil effectively treats hair loss with increased hair growth as a side effect, and low doses are generally safe.
28 citations
,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
September 2006 in “Aktuelle Urologie” Combination drug therapies are more effective for high-risk BPS patients but have more side effects and costs.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
22 citations
,
April 1985 in “Australasian Journal of Dermatology” Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.
September 2025 in “Healthcare” SSRIs may help manage sexual behavior in dementia patients, but they can cause long-lasting sexual dysfunction.
Spironolactone with an oral contraceptive improved hair growth in women with hirsutism.
7 citations
,
November 2014 in “Clinical Therapeutics” Finasteride and tamsulosin hydrochloride can be safely taken together without significant interaction.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
May 2011 in “Utrecht University Repository (Utrecht University)” The nicotinamide supplement did not reduce symptoms in horses with insect bite hypersensitivity.
October 2019 in “UNESP Institutional Repository (São Paulo State University)” Oral minoxidil 1 mg is effective and safe for female hair loss, with less shedding but more hair growth on the body.
2 citations
,
January 2023 in “Respiratory Medicine Case Reports” Minoxidil can cause lung disease that looks like hypersensitivity pneumonitis.
11 citations
,
April 2009 in “Pharmacotherapy” Minoxidil can cause deadly skin reaction; monitor patients closely.
April 2025 in “Research Square (Research Square)” Minoxidil microinfusion lowered diastolic blood pressure in patients.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
2 citations
,
June 2009 in “PubMed”
These medications for BPH have known risks and may have new side effects.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
23 citations
,
March 1988 in “Biochemical Pharmacology” Minoxidil stops cells from making prostacyclin, which may help with hair growth. More research is needed.
August 2025 in “Journal of Cosmetic Dermatology” Oral minoxidil users, especially for hypertension, may risk heart issues, and better monitoring guidelines are needed for alopecia patients.
15 citations
,
November 2015 in “Pharmacopsychiatry” α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
11 citations
,
September 2022 in “Journal of the Endocrine Society” Young transgender, gender diverse, and nonbinary people on spironolactone have a low risk of high potassium, so frequent monitoring may not be needed.